Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

basroparib

An orally bioavailable inhibitor of the poly (ADP-ribose) polymerase (PARP) enzyme tankyrase, with potential antineoplastic activity. Upon administration, basroparib selectively binds to and inhibits the activity of tankyrase. This may block the tankyrase-mediated poly(ADP-ribosyl)ation of multiple target proteins including various tumor suppressors. This may include the blockage of the poly(ADP-ribosyl)ation and destabilization of AXIN, a negative regulator of beta-catenin, and prevents Wnt/beta-catenin signaling. This may inhibit the activation of transcription of a wide range of target genes of Wnt/beta-catenin signaling, thereby preventing gene expression of many Wnt-related, pro-survival proteins and suppressing tumor cell growth. Tankyrase, a member of the PARP family, plays an important role in the regulation of the Wnt/beta-catenin signaling pathway, tumor suppressors, as well as telomere maintenance and mitosis regulation.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:tankyrase inhibitor STP1002
Code name:STP 1002
STP-1002
STP1002
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search